Expansion strengthens biotech capabilities and meets rising demand for complex drug production
Essen, Germany, 28 April 2026 – In a major move to strengthen its presence in the biotechnology sector, Evonik Industries has announced an investment of around 80 million euros to expand its biopharmaceutical manufacturing capacity in Slovakia. The development highlights the growing importance of biotechnology in modern healthcare and drug production.
The investment will be made at the company’s Fermas facility in Slovenská Ľupča, where new fermentation technology will be introduced to improve the production of pharmaceutical ingredients. In simple terms, this technology uses biological processes to produce complex medicines more efficiently and at a larger scale.
The expansion is designed to support the company’s contract development and manufacturing services, commonly known as CDMO services. These services allow pharmaceutical companies to outsource drug production, helping them reduce costs and speed up the process of bringing medicines to market.
As demand for advanced and complex medicines continues to grow globally, the company is focusing on strengthening its capabilities to meet industry needs. The upgraded facility will enable more reliable, large-scale, and sustainable production of pharmaceutical ingredients.
The project is also expected to create new job opportunities, contributing to local economic growth while strengthening the region’s position as a biotechnology hub.
This is part of the company’s broader strategy to expand its biotechnology operations. Over the years, the facility has evolved into a modern biotech center supporting multiple industries, including healthcare and specialty chemicals.
The move reflects a wider trend in the industry, where companies are shifting toward biotechnology-driven solutions. These methods are seen as more sustainable and efficient compared to traditional chemical manufacturing processes, especially for high-value pharmaceutical products.
Overall, this investment highlights a strong push toward innovation in pharmaceutical manufacturing. By expanding its biotechnology capabilities, Evonik is positioning itself to meet future healthcare demands while supporting sustainable industrial growth.
